Neoadjuvant Ipilimumab Nivolumab Melanoma Survival Biomarkers
- Teh authors of this paper declare no financial support was received for the work, and no medical writer contributed to its preparation, though several authors have disclosed relevant...
- Transparency regarding potential conflicts of interest is crucial in medical research to maintain the integrity and credibility of findings.
- has served on advisory boards for Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Roche, Pierre Fabre and QBiotics.
Competing Interests
Teh authors of this paper declare no financial support was received for the work, and no medical writer contributed to its preparation, though several authors have disclosed relevant affiliations and financial relationships.
Details
Transparency regarding potential conflicts of interest is crucial in medical research to maintain the integrity and credibility of findings. Authors are ethically obligated to disclose any relationships that could be perceived as influencing their work. these relationships can include financial support,advisory board memberships,speaker’s honoraria,research grants,and consultancy roles. Disclosures allow readers to assess potential biases and interpret the research accordingly.
examples
Specifically, A.M.M. has served on advisory boards for Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Roche, Pierre Fabre and QBiotics. R.P.M.S. received honoraria for advisory board participation from Merck Sharp & Dohme and Clinical Laboratories Pty Ltd. W.J.v.H. received speaker’s honoraria from Regeneron Pharmaceuticals, Sanofi, Merck Sharp & Dohme, Belpharma and novartis, and reports an advisory role with Belpharma, as well as a research grant from amgen. E.K. has consultancy/advisory relationships with Delcath, Immunocore and Lilly and received research grants unrelated to this paper from Bristol Myers Squibb, Delcath, Novartis and Pierre Fabre. A.A.M.v.d.V. received travel fees from Ipsen and consultancy fees (paid to the institution) from Bristol myers Squibb, Merck Sharp & Dohme, Ipsen, Eisai, Pfizer, and Novartis.